Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma

Cancer Immunology, Immunotherapy

Volumn 57, Issue 1, 2008, Pages 97-106

  Hillen, Femke ^a   Baeten, Coen I M ^a   Van De Winkel, Anouk ^a   Creytens, David ^a   Van Der Schaft, Daisy W J ^a   Winnepenninckx, Véronique ^a   Griffioen, Arjan W ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Activation status of lymphocytes; Angiogenesis; Cutaneous melanoma; Immunosuppression; Prognosis; Tumor cell plasticity; Tumor infiltrating leukocytes

Indexed keywords

CD16 ANTIGEN; CD69 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER STAGING; CELL COUNT; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUTROPHIL CHEMOTAXIS; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MELANOMA; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 35748930538     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0353-9     Document Type: Article

References (75)

1. Ramirez-Montagut T, et al (2003) Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22(20):3180-3187
2. Chen Q, Wang WC, Evans SS (2003) Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 52(11):670-679
3. Vesalainen S, et al (1994) Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 30A(12):1797-1803
4. Marrogi AJ, et al (1997) Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 74(5):492-501
5. Chao HT, et al (1999) Lymphocyte-infiltrated FIGO Stage IIB squamous cell carcinoma of the cervix is a prominent factor for disease-free survival. Eur J Gynaecol Oncol 20(2):136-140
6. Naito Y, et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58(16):3491-3494
7. Schumacher K, et al (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61(10):3932-3936
8. Cho Y, et al (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63(7):1555-1559
9. Zhang L, et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203-213
10. Sato E, et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102(51):18538-18543
11. Badoual C, et al (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12(2):465-472
12. Hiraoka K, et al (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94(2):275-280
13. Hussein MR (2005) Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight. Br J Dermatol 153(1):18-21
14. Clark WH Jr, et al (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81(24):1893-1904
15. Clemente CG, et al (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7):1303-1310
16. Thorn M, et al (1994) Trends in tumour characteristics and survival of malignant melanoma 1960-84: a population-based study in Sweden. Br J Cancer 70(4):743-748
17. Barnhill RL, et al (1996) Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78(3):427-432
18. van der Schaft DW, et al (2005) Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 65(24):11520-11528
19. Hillen F, et al (2006) Proliferating endothelial cells, but not microvessel density, is a prognostic parameter in human cutaneous melanoma. Melanoma Res 16:453-457
20. Warso MA, et al (2001) Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 7(3):473-477
21. Hendrix MJ, et al (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3(6):411-421
22. Thies A, et al (2001) PAS-positive loops and networks as a prognostic indicator in cutaneous malignant melanoma. J Pathol 195(5):537-542
23. Levi F, et al (2004) Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int J Cancer 110(2):155-169
24. Carlson JA, et al (2003) Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol 120(Suppl):S101-S127
25. Eberlein TJ, Rosenstein M, Rosenberg SA (1982) Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med 156(2):385-397
26. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233(4770):1318-1321
27. Overwijk WW, et al (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188(2):277-286
28. Dudley ME, et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850-854
29. Yee C, et al (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99(25):16168-16173
30. Dudley ME, et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346-2357
31. Morgan RA, et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796):126-129
32. Hussein MR, et al (2006) Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J Clin Pathol 59(3):316-324
33. Brocker EB, et al (1988) Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 41(4):562-567
34. Piras F, et al (2005) The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104(6):1246-1254
35. Jorkov AS, et al (2003) Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride. Anticancer Res 23(1B):537-542
36. Jovic V, et al (2001) Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma. Tumori 87(5):324-329
37. Mantovani A, et al (1992) The origin and function of tumor-associated macrophages. Immunol Today 13(7):265-270
38. Bingle L, Brown NJ, Lewis CE (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196(3):254-265
39. Dirkx AEM, et al (2006) Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80(6):1183-1196
40. Bennett SR, et al (1998) B cells directly tolerize CD8(+) T cells. J Exp Med 188(11):1977-1983
41. Perricone MA, et al (2004) Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 27(4):273-281
42. Shah S, et al (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 117(4):574-586
43. Lapointe R, et al (2003) CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 63(11):2836-2843
44. Martinez-Escribano JA, et al (2003) Changes in the number of CD80(+), CD86(+), and CD28(+) peripheral blood lymphocytes have prognostic value in melanoma patients. Hum Immunol 64(8):796-801
45. Aklilu M, et al (2004) Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 15(7):1109-1114
46. Massague J (1990) The transforming growth factor-beta family. Annu Rev Cell Biol 6:597-641
47. Fiorentino DF, et al (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146(10):3444-3451
48. Ladanyi A, et al (2004) T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 10(2):521-530
49. Rubinstein N, et al (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5(3):241-251
50. Le QT, et al (2005) Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23(35):8932-8941
51. Pawelec G (2004) Tumour escape from the immune response. Cancer Immunol Immunother 53(10):843
52. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057-1061
53. Woo EY, et al (2001) Regulatory CD4(+) CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61(12):4766-4772
54. Woo EY, et al (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168(9):4272-4276
55. Sasada T, et al (2003) CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98(5):1089-1099
56. Wolf AM, et al (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9(2):606-612
57. Viguier M, et al (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173(2):1444-1453
58. Alvaro T, et al (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11(4):1467-1473
59. Wolf D, et al (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11(23):8326-8331
60. Hiraoka N, et al (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12(18):5423-5434
61. Bates GJ, et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373-5380
62. Appay V, et al (2006) New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 177(3):1670-1678
63. Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107(6):2409-2414
64. Nair S, et al (2007) Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 67(1):371-380
65. Cambiaggi C, et al (1992) Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12. Immunogenetics 36(2):117-120
66. Healy CG, et al (1998) Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32(2):109-119
67. Koch M, et al (2006) Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg 244(6):986-992; discussion 992-3
68. Slingluff CL Jr, et al (1988) Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg 208(2):150-161
69. Blessing K, McLaren KM (1992) Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 20(4):315-322
70. Trau H, et al (1983) Metastases of thin melanomas. Cancer 51(3):553-556
71. Wanebo HJ, Cooper PH, Hagar RW (1985) Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression. Ann Surg 201(4):499-504
72. Shaw HM, et al (1987) Thin malignant melanomas and recurrence potential. Arch Surg 122(10):1147-1150
73. Fontaine D, et al (2003) Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? Am J Dermatopathol 25(5):371-376
74. Molema G, Griffioen AW (1998) Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol Today 19(9):392-394
75. Maniotis AJ, et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155(3):739-752